Eyevensys appoints Dr Garth Cumberlidge to its Board of Directors as Chairman

– FRANCE, Paris – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, announces that Dr.